Genmab A/S Reduces Share Capital by Cancelling Treasury Shares Following Buyback
GMAB sits 48% above its 52-week low of $17.235 on light trading volume (0.1× avg).
Summary
Genmab's Annual General Meeting approved the cancellation of treasury shares, formally reducing its share capital after completing an $89 million buyback program.
Key Events · Financing and Capital Events · GMAB
-
Share Capital Reduction Approved
Shareholders approved the reduction of the company's share capital by nominally DKK 1,900,000 through the cancellation of treasury shares.
-
Formalizes Prior Buyback
This action follows the completion of the company's $89 million share buyback program, announced on March 16, 2026, and formally reduces the number of outstanding shares.
-
Routine AGM Approvals
The Annual Report for 2025 and the 2025 Compensation Report were approved, and the Board of Directors and Executive Management were discharged. Six board members and the auditor were re-elected.
Analysis · GMAB · Life Sciences
The company's Annual General Meeting approved a proposal to reduce share capital by cancelling treasury shares. This action formalizes the reduction in outstanding shares resulting from the recently completed $89 million share buyback program, enhancing shareholder value by increasing earnings per share. This move demonstrates a commitment to returning capital to shareholders and optimizing the capital structure.
At the time of this filing, GMAB was trading at $25.59 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $15.8B. The 52-week trading range was $17.24 to $35.43. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.